Clinical Trial Detail

NCT ID NCT01994382
Title Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Portola Pharmaceuticals
Indications

diffuse large B-cell lymphoma

follicular lymphoma

CLL/SLL

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

mantle cell lymphoma

lymphoplasmacytic lymphoma

Therapies

Cerdulatinib

Age Groups: adult

No variant requirements are available.